Results 221 to 230 of about 520,866 (339)

The nucleotide sequence of bovine MHC class II DQB and DRB genes

Immunogenetics, 2004
M. Groenen, J. J. Poel, R. Dijkhof, M. Giphart   +3 more
semanticscholar   +1 more source

Engineering and Structural Elucidation of a Sac7d‐Derived IgG Fc‐Specific Affitin and Its Application for the Light‐Controlled Affinity Purification of Antibodies

ChemBioChem, EarlyView.
An affitin derived from the Sac7d scaffold enables the light‐controlled affinity purification of antibodies under physiological conditions, thus overcoming limitations of protein A chromatography. X‐ray crystallographic analysis and affinity measurements reveal complex formation with Fc at the CH2/CH3 junction, similar to protein A/G and FnRn. Combined
Felix Veitl, Andreas Eichinger, Peter Mayrhofer, Markus R. Anneser, Mauricio Testanera, Kilian Rauscher, Matthias Lenz, Arne Skerra   +7 more
wiley   +1 more source

Knockdown of TIM3 Hampers Dendritic Cell Maturation and Induces Immune Suppression by Modulating T-Cell Responses. [PDF]

Int J Mol Sci
Chen S, Chen J, Kong Y, Li H, Chen Z, Luo L, Wu Y, Chen L.   +7 more
europepmc   +1 more source

Identification of Natural Killer Cell Enhancers Through Mimicking of the Tumor Microenvironment

Chemistry – A European Journal, Volume 31, Issue 18, March 25, 2025.
The ability of natural killer (NK) cells to identify and eliminate cancer cells is reduced within the tumor microenvironment (TME), allowing cancer to evade detection and eradication by immune cells. We developed a novel co‐culture assay that replicates the immunosuppressive TME conditions to facilitate the discovery of compounds that can prevent NK ...
Aylin Binici, Elisabeth Hennes, Sandra Koska, Jens Alexander Niemann, Alisa Reich, Christiane Pfaff, Sonja Sievers, Astrid Stefanie Kahnt, Dominique Thomas, Slava Ziegler, Carsten Watzl, Herbert Waldmann   +11 more
wiley   +1 more source

Supercharged NK cells, unlike primary activated NK cells, effectively target ovarian cancer cells irrespective of MHC-class I expression. [PDF]

BMJ Oncol
Huerta-Yepez S, Chen PC, Kaur K, Jain Y, Singh T, Esedebe F, Liao YJ, DiBernardo G, Moatamed NA, Mei A, Malarkannan S, Graeber TG, Memarzadeh S, Jewett A.   +13 more
europepmc   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

The Amphibian Major Histocompatibility Complex-A Review and Future Outlook. [PDF]

J Mol Evol
Sabino-Pinto J, Maan ME.
europepmc   +1 more source

Immune Checkpoint Inhibitors and Cardiovascular Adverse Events

ESC Heart Failure, EarlyView.
Abstract In the last years, we assisted to a tremendous increase in therapeutic options for the management of cancers, with immunotherapy at the forefront of this innovation. Immune checkpoint inhibitors (ICIs) have been developed to enhance the activity of the immune system against cancer cells (1) and the number of approvals for ICIs has rapidly ...
Maria Luisa De Perna, Elia Rigamonti, Raffaele Zannoni, Vittoria Espeli, Giorgio Moschovitis   +4 more
wiley   +1 more source

Neoantigens: new hope for cancer therapy. [PDF]

Front Oncol
Hu Y, Zhou T, Cai P, He Z.
europepmc   +1 more source

Update on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio‐Oncology, and the ESC Working Group on Cellular Biology of the Heart

European Journal of Heart Failure, EarlyView.
New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the ...
Alessandra Ghigo, Pietro Ameri, Aarti Asnani, Edoardo Bertero, Rudolf A. de Boer, Dimitrios Farmakis, Arantxa González, Stephane Heymans, Borja Ibáñez, Teresa López‐Fernández, Alexander R. Lyon, Piero Pollesello, Amina Rakisheva, Konstantinos Stellos, Katrin Streckfuss‐Bömeke, Carlo Gabriele Tocchetti, Thomas Thum, Peter van der Meer, Eva Van Rooij, Piotr Ponikowski, Marco Metra, Giuseppe Rosano, Sophie Van Linthout   +22 more
wiley   +1 more source